[go: up one dir, main page]

CN113330036A - 结合pd-l1和ox40的双特异性抗体 - Google Patents

结合pd-l1和ox40的双特异性抗体 Download PDF

Info

Publication number
CN113330036A
CN113330036A CN202080010761.9A CN202080010761A CN113330036A CN 113330036 A CN113330036 A CN 113330036A CN 202080010761 A CN202080010761 A CN 202080010761A CN 113330036 A CN113330036 A CN 113330036A
Authority
CN
China
Prior art keywords
antibody
amino acid
antigen
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080010761.9A
Other languages
English (en)
Other versions
CN113330036B (zh
Inventor
匡智慧
刘心义
陈炳良
刘军建
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovent Biologics Suzhou Co Ltd
Original Assignee
Innovent Biologics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics Suzhou Co Ltd filed Critical Innovent Biologics Suzhou Co Ltd
Publication of CN113330036A publication Critical patent/CN113330036A/zh
Application granted granted Critical
Publication of CN113330036B publication Critical patent/CN113330036B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

一种经人工设计的抗体分子，特别是抗PD‑L1/OX40双特异性抗体分子，其能同时结合PD‑L1和OX40。

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN202080010761.9A 2019-01-25 2020-01-23 结合pd-l1和ox40的双特异性抗体 Active CN113330036B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910073250 2019-01-25
CN2019100732500 2019-01-25
PCT/CN2020/073959 WO2020151761A1 (zh) 2019-01-25 2020-01-23 结合pd-l1和ox40的双特异性抗体

Publications (2)

Publication Number Publication Date
CN113330036A true CN113330036A (zh) 2021-08-31
CN113330036B CN113330036B (zh) 2023-04-28

Family

ID=71736393

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080010761.9A Active CN113330036B (zh) 2019-01-25 2020-01-23 结合pd-l1和ox40的双特异性抗体

Country Status (3)

Country Link
CN (1) CN113330036B (zh)
TW (1) TWI793395B (zh)
WO (1) WO2020151761A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022553176A (ja) * 2019-10-17 2022-12-22 江蘇康寧杰瑞生物制薬有限公司 Ｏｘ４０／ｐｄ－ｌ１二重特異性抗体
CN114106190B (zh) * 2020-08-31 2025-04-08 普米斯生物技术(珠海)有限公司 一种抗vegf/pd-l1双特异性抗体及其用途
CN117098780A (zh) * 2021-04-26 2023-11-21 天境生物科技(上海)有限公司 单域pd-l1抗体
CN115505045A (zh) * 2021-06-23 2022-12-23 迈威(上海)生物科技股份有限公司 靶向lag-3和pd-l1的新型双特异抗体及其应用
CN114478789B (zh) * 2021-12-20 2024-06-14 安徽安科生物工程（集团）股份有限公司 抗pd-l1与ox40双特异性抗体及其用途
CN117186223B (zh) * 2022-05-31 2024-08-09 明济生物制药（北京）有限公司 抗pd-l1抗体及编码其的核酸、制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018014855A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
CN107686520A (zh) * 2016-08-04 2018-02-13 信达生物制药(苏州)有限公司 抗pd‑l1纳米抗体及其应用
CN107750164A (zh) * 2015-06-08 2018-03-02 豪夫迈·罗氏有限公司 使用抗ox40抗体和pd‑1轴结合拮抗剂治疗癌症的方法
CN108623685A (zh) * 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
CN108883153A (zh) * 2016-01-11 2018-11-23 印希比股份有限公司 多价和多特异性ox40结合融合蛋白
CN109195994A (zh) * 2016-04-22 2019-01-11 鳄鱼生物科学公司 针对cd137的新型双特异性多肽

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201500319D0 (en) * 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
WO2017132827A1 (en) * 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
CN108623686A (zh) * 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
KR20200002889A (ko) * 2017-05-02 2020-01-08 엘리게이터 바이오사이언스 에이비 Ox40 및 ctla-4에 대한 이중특이적 항체

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107750164A (zh) * 2015-06-08 2018-03-02 豪夫迈·罗氏有限公司 使用抗ox40抗体和pd‑1轴结合拮抗剂治疗癌症的方法
CN108883153A (zh) * 2016-01-11 2018-11-23 印希比股份有限公司 多价和多特异性ox40结合融合蛋白
CN109195994A (zh) * 2016-04-22 2019-01-11 鳄鱼生物科学公司 针对cd137的新型双特异性多肽
WO2018014855A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
CN107686520A (zh) * 2016-08-04 2018-02-13 信达生物制药(苏州)有限公司 抗pd‑l1纳米抗体及其应用
CN108623685A (zh) * 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GUO, ZQ等: "PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer" *
刘弋维等: "PD-1/PD-L1抑制剂研究进展" *

Also Published As

Publication number Publication date
TW202043278A (zh) 2020-12-01
CN113330036B (zh) 2023-04-28
TWI793395B (zh) 2023-02-21
WO2020151761A1 (zh) 2020-07-30

Similar Documents

Publication Publication Date Title
CN110536903B (zh) 抗ox40抗体及其用途
RU2765306C2 (ru) Антитело против в7-н3, его антигенсвязывающий фрагмент и их медицинское применение
CN113330036B (zh) 结合pd-l1和ox40的双特异性抗体
CN110305210B (zh) 新型抗体分子、其制备方法及其用途
WO2021259199A1 (zh) 抗cd73抗体及其用途
CN119350498A (zh) 一种抗体及其用途
TWI756621B (zh) 新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
TWI837517B (zh) 抗claudin 18.2和cd3的雙特異性抗體以及其用途
WO2020156439A1 (zh) 抗cd79b抗体、其抗原结合片段及其医药用途
EP4458854A1 (en) Gprc5d antibody and application thereof
CN113366020B (zh) 抗pd-l1的新型抗体及其用途
CN111918878A (zh) 抗gitr抗体及其用途
WO2021175191A1 (zh) 抗tim-3抗体及其用途
EP4382538A1 (en) Anti-cd79b×cd3 bispecific antibody and use thereof
WO2025051083A1 (zh) 抗bdca-2特异性抗体及其用途
JP2024509369A (ja) 抗ｐｄ－ｌ１抗体及びその使用
TW202241957A (zh) 抗ｐｄ－１抗體及其用途
WO2000052470A1 (fr) Moyen de diagnostic et de traitement de la leucemie

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant